<!doctype html><html lang="en"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,user-scalable=no,initial-scale=1,maximum-scale=1,minimum-scale=1"><meta http-equiv="X-UA-Compatible" content="ie=edge"><title>Ad Banners</title><script>window.type = "mpu";</script><script defer="defer" src="main.js"></script><link href="main.css" rel="stylesheet"></head><body><div class="banner mpu"><main id="main"><div class="carousel" data-slide="0" style="--slide: 0"><div class="carousel-slides"><div class="carousel-slide carousel-slide-0" style="background-image: url('mpu-background.jpg')"><h3>Launching in the UK IN 2022</h3></div><div class="carousel-slide carousel-slide-1" style="background-image: url('mpu-background.jpg')"><h3><span>A</span> <span>NEW</span> <span>ADVANCE</span> <span>IN</span> <span>THE</span> <span>TREATMENT</span> <span>OF</span> <span>DRAVET</span> <span>SYNDROME</span></h3></div><div class="carousel-slide carousel-slide-2" style="background-image: url('mpu-background.jpg')"><h3>Join us for the launch meeting â€“<br>in person or online</h3></div><div class="carousel-slide carousel-slide-3" style="background-image: url('mpu-background.jpg')"><div class="button"><span>REGISTER<br>YOUR INTEREST</span> <img src="triangle.svg" alt=""></div><div class="description"><p>Fintepla is indicated for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.<sup>1</sup></p><ol><li>Fintepla Summary of Product Characteristics.</li></ol></div></div></div></div><img class="logo" src="logo.svg" alt="ZOGENIX"><div class="disclaimer">Fintepla is currently<br>under NICE evaluation</div></main><aside><div class="legal" id="legal"><p><strong>Click here for Fintepla prescribing information & Adverse Event reporting</strong></p><p><strong>UK-FIN1-2100095 | December 2021</strong></p></div><img src="fintepla-logo.svg" alt="Fintepla"></aside></div></body></html>